Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480HONG XIN; HERRMANN, Andreas; MOROSINI, Deborah et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 21, pp 6601-6610, issn 0008-5472, 10 p.Article

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid LeukemiaLEE, Hun Ju; DAVER, Naval; KANTARJIAN, Hagop M et al.Clinical cancer research (Print). 2013, Vol 19, Num 2, pp 327-335, issn 1078-0432, 9 p.Article

Janus Kinase MutationsLEVINE, Ross L.Seminars in oncology. 2009, Vol 36, Num 2, issn 0093-7754, S6-S11, SUP1Article

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspectiveTEFFERI, A; PARDANANI, A.Blood reviews. 2011, Vol 25, Num 5, pp 229-237, issn 0268-960X, 9 p.Article

Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264.7 cells through suppressing JAK-STAT signal pathwayXIANJUAN KOU; SHIMEI QI; WUXING DAI et al.International immunopharmacology (Print). 2011, Vol 11, Num 8, pp 1095-1102, issn 1567-5769, 8 p.Article

Janus Kinase V617F mutation in cigarette smokersWEINBERG, Ido; BOROHOVITZ, Ariel; KRICHEVSKY, Svetlana et al.American journal of hematology. 2012, Vol 87, Num 1, pp 5-8, issn 0361-8609, 4 p.Article

Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase InhibitorsMEYER, Sara C; LEVINE, Ross L.Clinical cancer research (Print). 2014, Vol 20, Num 8, pp 2051-2059, issn 1078-0432, 9 p.Article

The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compoundsKAO, Kenneth K; FINK, Mitchell P.Biochemical pharmacology. 2010, Vol 80, Num 2, pp 151-159, issn 0006-2952, 9 p.Article

Metabolism, Excretion, and Pharmacokinetics of [¹⁴C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in HumansSHILLING, Adam D; NEDZA, Frank M; SHEPARD, Stacey et al.Drug metabolism and disposition. 2010, Vol 38, Num 11, pp 2023-2031, issn 0090-9556, 9 p.Article

IRF9 is a Key Factor for Eliciting the Antiproliferative Activity of IFN-αTSUNO, Takaya; MEJIDO, Josef; ZHAO, Tongmao et al.Journal of immunotherapy (1997). 2009, Vol 32, Num 8, pp 803-816, issn 1524-9557, 14 p.Article

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from mythsTEFFERI, Ayalew.Blood. 2012, Vol 119, Num 12, pp 2721-2730, issn 0006-4971, 10 p.Article

Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid ArthritisVYAS, Deepti; O'DELL, Kate M; BANDY, Jason L et al.The Annals of pharmacotherapy. 2013, Vol 47, Num 11, pp 1524-1531, issn 1060-0280, 8 p.Article

Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer CompoundsRIOS, J. L; ANDUJAR, I; ESCANDELL, J. M et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 12, pp 1663-1676, issn 1381-6128, 14 p.Article

Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cellsVOLLMER, Stefan; HAAN, Claude; BEHRMANN, Iris et al.Biochemical pharmacology. 2010, Vol 80, Num 12, pp 2066-2073, issn 0006-2952, 8 p.Conference Paper

Safety evaluation of ruxolitinib for treating myelofibrosisGALLI, Sofia; MCLORNAN, Donal; HARRISON, Claire et al.Expert opinion on drug safety. 2014, Vol 13, Num 7, pp 967-976, issn 1474-0338, 10 p.Article

Therapeutic Targeting of the JAK/STAT PathwayAITTOMÄKI, Saara; PESU, Marko.Basic & clinical pharmacology & toxicology (Print). 2014, Vol 114, Num 1, pp 18-23, issn 1742-7835, 6 p.Conference Paper

Genomic profiling of high-risk acute lymphoblastic leukemiaCOLLINS-UNDERWOOD, J. R; MULLIGHAN, C. G.Leukemia. 2010, Vol 24, Num 10, pp 1676-1685, issn 0887-6924, 10 p.Article

17-Hydroxy-jolkinolide B Inhibits Signal Transducers and Activators of Transcription 3 Signaling by Covalently Cross-Linking Janus Kinases and Induces Apoptosis of Human Cancer CellsYING WANG; XIUQUAN MA; SHOUSHENG YAN et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 18, pp 7302-7310, issn 0008-5472, 9 p.Article

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinibYAMAOKA, Kunihiro; TANAKA, Yoshiya.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 1, pp 103-113, issn 1465-6566, 11 p.Article

6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma CellsLIU, Lucy; NAM, Sangkil; JOVE, Richard et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 11, pp 3972-3979, issn 0008-5472, 8 p.Article

Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNSDELL'ALBANI, P; SANTANGELO, R; TORRISI, L et al.Neurochemical research. 2003, Vol 28, Num 1, pp 53-64, issn 0364-3190, 12 p.Article

Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid ArthritisKAUR, Kirandeep; KALRA, Sonesh; KAUSHAL, Sandeep et al.Clinical therapeutics. 2014, Vol 36, Num 7, pp 1074-1086, issn 0149-2918, 13 p.Article

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012MCLORNAN, Donal P; MEAD, Adam J; JACKSON, Graham et al.British journal of haematology. 2012, Vol 157, Num 4, pp 413-425, issn 0007-1048, 13 p.Article

Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cellXIAOLI ZHANG; YAJUAN SONG; ZHENGFANG YI et al.International journal of cancer (Print). 2011, Vol 129, Num 10, pp 2502-2511, issn 0020-7136, 10 p.Article

Iron Chelators and Hypoxia Mimetics Inhibit IFNy-Mediated Jak-STAT SignalingGIRA, Amy K; KOWALCZYK, Andrew P; YUE FENG et al.Journal of investigative dermatology. 2009, Vol 129, Num 3, pp 723-729, issn 0022-202X, 7 p.Article